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Abstract
Background: Asthma is a respiratory tract disorder characterized by airway hyper-reactivity and chronic inflammation.
Allergic asthma is associated with the production of allergen-specific IgE and expansion of allergen-specific T-cell
populations. Progression of allergic inflammation is driven by T-helper type 2 (Th2) mediators and is associated with
alterations in the levels of lipid mediators.
Objectives: Responses of the respiratory system to birch allergen provocation in allergic asthmatics were investigated.
Eicosanoids and other oxylipins were quantified in the bronchoalveolar lumen to provide a measure of shifts in lipid
mediators associated with allergen challenge in allergic asthmatics.
Methods: Eighty-seven lipid mediators representing the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450
(CYP) metabolic pathways were screened via LC-MS/MS following off-line extraction of bronchoalveolar lavage fluid (BALF).
Multivariate statistics using OPLS were employed to interrogate acquired oxylipin data in combination with immunological
markers.
Results: Thirty-two oxylipins were quantified, with baseline asthmatics possessing a different oxylipin profile relative to
healthy individuals that became more distinct following allergen provocation. The most prominent differences included 15-
LOX-derived v-3 and v-6 oxylipins. Shared-and-Unique-Structures (SUS)-plot modeling showed a correlation (R
2=0.7)
between OPLS models for baseline asthmatics (R
2Y[cum]=0.87, Q
2[cum]=0.51) and allergen-provoked asthmatics
(R
2Y[cum]=0.95, Q
2[cum]=0.73), with the majority of quantified lipid mediators and cytokines contributing equally to both
groups. Unique structures for allergen provocation included leukotrienes (LTB4 and 6-trans-LTB4), CYP-derivatives of linoleic
acid (epoxides/diols), and IL-10.
Conclusions: Differences in asthmatic relative to healthy profiles suggest a role for 15-LOX products of both v-6 and v-3
origin in allergic inflammation. Prominent differences at baseline levels indicate that non-symptomatic asthmatics are
subject to an underlying inflammatory condition not observed with other traditional mediators. Results suggest that
oxylipin profiling may provide a sensitive means of characterizing low-level inflammation and that even individuals with
mild disease display distinct phenotypic profiles, which may have clinical ramifications for disease.
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Asthma is a respiratory tract disorder with global implications
that is characterized by airway hyper-responsiveness and chronic
airway inflammation [1,2,3,4]. The disease is frequently associated
with increased IgE-mediated sensitization and correlates with
other allergic diseases including eczema and rhinitis [5,6]. Allergic
asthma is characterized by allergen-specific IgE antibody produc-
tion and secretion of Th2 cytokines (e.g., IL-4 and IL-13) by T-
helper cells with subsequent activation of mast cells, eosinophil
infiltration and airway smooth muscle constriction [7,8,9,10].
Lipid mediators in the form of oxidized fatty acids (oxylipins) are
known markers of early asthmatic and anaphylactic patient
responses to allergens [11,12,13,14]. Oxylipins are biosynthesized
from unsaturated fatty acids via three main pathways: lipoxygen-
ase (LOX), cyclooxygenase (COX) and cytochrome P450 (CYP)
[15,16]. Oxylipins include the well-known eicosanoids synthesized
from arachidonic acid (AA; e.g., leukotrienes and prostaglandins),
as well as mediators synthesized from other related v-6 and v-3
fatty acids (fatty acids containing the initial double bond 6 or 3
carbons respectively from the terminal methyl group of the fatty
acid backbone) [17,18].
The roles of specific oxylipins in the etiology and pathology of
asthma have been extensively reported [19,20,21,22,23,24,25]. In
particular, oxylipins regulated by the COX and LOX pathways
have been shown to be elevated, both at baseline levels and/or
following provocation, in allergic asthma [13,14,26,27,28]. For
example, in asthmatics the cysteinyl-leukotrienes exert a causative
role in allergen-induced airway inflammation through selective
increase ineosinophils intheairways[22],and prostaglandin aswell
as the 15-LOX product 15-hydroxyeicosatetraenoic acid (15-
HETE) production increases following allergen exposure [29]. 15-
LOX, in particular is significantly elevated in epithelial cells in the
airways of asthmatic subjects [30,31,32] and regulated by the
cytokines IL-4 and IL-13 [33,34]. 15-LOX activity has been
hypothesizedtohave bothpro-inflammatoryand anti-inflammatory
characteristics in the lung [31,32,35,36]. For instance, the primary
15-LOX product formed from AA, 15-hydroperoxyeicosatetrae-
noic acid (HpETE), can be dehydrated to pro-inflammatory 14,15-
leukotriene derivatives (eoxins) [37,38], or serve as the precursor to
the anti-inflammatory lipoxins [39]. A protective function for 15-
LOXhasalsobeen demonstratedbyitsrole intheformationofv-3-
derived resolvins and protectins [17,40]. Accordingly, oxylipin
biology is a complex interaction of pro- and anti-inflammatory
signals that are dependent upon the temporal sequence of
production, and should be examined within the context of the
complex milieu of resident pulmonary cells and infiltrating
inflammatory cells as well as interactions with other nonlipid
inflammatory mediators. In addition, dietary shifts in fatty acid
consumption can affect oxylipin levels and speciation [41].
In this study, we quantified oxylipins in bronchoalveolar lavage
fluid (BALF) from mild allergic asthmatics 24 h following birch
pollen provocation compared to baseline levels in both asthmatic
and healthy control subjects. An oxylipin metabolic profiling
approach was applied in which a broad selection of compounds
were quantified representing major components of the relevant
biological pathways. Multivariate statistics were used to correlate
oxylipin levels with clinical parameters, cytokines, and data from
analysis of cells and inflammation markers by fluorescence
activating cell sorting (FACS). This approach demonstrates the
utility of applying a broad scale metabolic profiling method to
investigate mechanisms in asthma, and particularly the integrative
power of combininganalytical data with patient clinical information
using multivariate statistics.
Methods
Clinical data and study design
Detailed descriptions of the subjects and study design are
provided elsewhere [42]. Briefly, 8 birch pollen allergic patients
with mild asthma (age 22–42 years, 4 females) and 10 non-allergic
healthy control subjects (age 22–37 years, 5 females) were included
in the present study (Table 1). All asthmatic patients had allergen-
specific IgE to inhaled birch pollen (.2 kU/l), while non-allergic
controls were negative (,0.35 kU/l) to PhadiatopH (a mix of
common inhalant allergens, Immuno CAP System, Phadia AB,
Uppsala, Sweden). Allergen challenge was performed by inhala-
tion using doses required for 20% drop in FEV1 as shown in
Table 1. Asthmatic subjects were asymptomatic, with stable mild
intermittent disease, with occasional use of inhaled short-acting
b2-agonists. The wash out period was a minimum of 4 weeks for
inhaled steroid use following exacerbations, and a 2 week
minimum for anti-histamines, anti-leukotrienes and non-steroidal
anti-inflammatory drugs (NSAIDs). Exacerbations and airway
infections were prohibited during the last 4 weeks prior to
sampling. The study was performed outside of birch pollen season.
Sampling by bronchoalveolar lavage (BAL) was carried out as
described previously [43] on all subjects at 1) unprovoked baseline
levels and 2) a second time point within 3 months, and with at least
14 days between the two time points, on the asthmatic subjects
following bronchoprovocation with birch pollen extract (Aquagen
SQ, ALK, Copenhagen, Denmark), corresponding to a final drop
Table 1. Clinical data of participating subjects.
Subject
a Diagnosis
b Age
c Gender
d FEV1%
e IgE birch
f
1A 4 2 F9 88
3 A 36 F 101 31
4A 2 2 M 8 82 0
6 A 32 F 104 5
7 A 34 F 101 3
8 A 25 M 102 54
12 A 24 M 82 16
13 A 24 M 103 100
4 H 37 M 117 N/A
5 H 25 M 120 N/A
6H 2 5 F9 6N / A
7
g H 26 F 97 N/A
8
g H 26 F 111 N/A
9
h H 22 M 99 N/A
10 H 25 M 99 N/A
11 H 23 F 99 N/A
12 H 24 F 99 N/A
13 H 26 M 105 N/A
aSubject numbering is presented as originally published by Thunberg et al. [42].
bAsthma (A), Healthy (H).
cAge in years at time of study inclusion.
dFemale (F), Male (M).
eFEV1% values at baseline. A Student’s t-test of the groups indicated that there
was no different between the two populations (p=0.11).
fkU/l required for 20% drop in FEV1%, as reported by Thunberg et al. [42].
gOxylipin profiling of subject 7 and 8 was performed in a pooled sample.
hIndividual 9 was incorrectly reported by Thunberg et al. [42] and is a 22 year
old male healthy individual.
doi:10.1371/journal.pone.0033780.t001
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carried out 24 h post-challenge. BALF was strained through a
Dacron net (Millipore, Bedford, Ireland), centrifuged at 400 g for
10 min at 4uC and kept at 280uC until use. All participants gave
their informed written consent and the study was approved by the
Stockholm Regional Ethics Committee (Case number 2005/1259-
31/2).
Oxylipin extraction and analysis
Analytical oxylipin standards, deuterated oxylipin internal
standards and the technical standard N-cyclohexyl-N9-dodecanoic
acid urea (CUDA, also termed a Type II internal standard [45])
were obtained from Cayman Chemical (Ann Arbor, MI, USA),
Larodan Fine Chemicals AB (Malmo ¨, Sweden), Enzo Life
Sciences (Farmingdale, NY, USA) or synthesized in-house [45].
A list of all standards is provided in the Supporting Information
(Table S1). Off-line solid-phase extraction (SPE) was performed
using Waters Oasis HBL 60 mg cartridge columns (Milford, MA,
USA) as previously described [45,46,47]. A detailed description of
the instrument method is given elsewhere [45]. An Agilent 1200
SL separation module (Santa Clara, CA, USA) coupled to ABI
4000 QTRAPH hybrid triple quadrupole/linear ion trap mass
spectrometer (Foster City, CA, USA) was used for analyses and
separation was performed via a 2.16150 mm Eclipse plus C18
column with a 1.8 mm particle size (Agilent, Santa Clara, CA,
USA). Oxylipins were quantified using internal standard methods
as previously described [45]. A sample chromatogram for the full
oxylipin metabolic profiling method is shown in Figure S1A. In
addition, Figure S1B displays the separation of 6-trans-LTB4 and
5,6-DiHETE from other purported isomers. However, due to a
lack of analytical standards, these other compounds were not
definitively identified or quantified and therefore are not reported
in either this study or previous publications [45,46,47]. Oxylipins
detected above the limit of quantification (LOQ) were quantified,
and the values shown in Table 2 are normalized by the BALF
recovery volume (V(Recovered volume)/V(Instilled volume)) [47]. Con-
centrations not adjusted for BALF recovery as well as BALF
recovery information are provided in Table S2 and Table S3,
respectively. The long-term stability of the full profile of oxylipins
in BALF has not been evaluated, but a recent study evaluated
stability in a range of conditions in cell culture [48].
Immunological markers
Bronchoalveolar lavage cells were cytospun and stained with
May-Gru ¨nwald-Giemsa, followed by differential counting of
macrophages, lymphocytes, eosinophils, neutophils and mast cells.
Cytokine levels in BALF were measured by cytometric bead array
analyses as previously reported [42]. Surface- and intracellular
staining of BAL cells followed by flow cytometry analyses of a
number of markers for common immune cells, as well as
activation/regulatory markers, were performed as earlier de-
scribed [42]. Four panels of FACS antibodies were used for the
analysis as described in Table S4. Data for some of the markers
have been published earlier [42]. The data used for multivariate
analysis and values presented in Table 3 represent percentage of
expressed markers in defined cell populations as listed in Table S5.
Statistical methods
The oxylipin data follow a normal or near-normal distribution
(Shaprio-Wilks p.0.01). Univariate statistical analysis was per-
formed using a Student’s t-test. No multiple hypothesis testing
correction was performed given that only 32 compounds were
present above the LOQ, which at an a=0.05 gives on average
,1.6 potential false positives. In addition, the primary findings of
the study focus on oxylipin products of the 15-LOX pathway
(n=15), which at an a=0.05 gives on average ,1 potential false
positives. Relative percent composition was analyzed by grouping
the lipid metabolites according to class. Trends in the shifts of 15-
LOX-derived oxylipins and in oxylipin relative composition were
evaluated between healthy and asthmatic controls, and asthmatics
following allergen provocation using the Cochran-Armitage trend
test [49]. The median value among the healthy controls for each
oxylipin (pM) or fatty acid relative class (%) was used as a cut off
limit for all three groups and all trend-based p values are one-
sided. Multivariate analyses using principal component analysis
(PCA) and orthogonal projections to latent structures (OPLS) were
performed using SIMCA-P+ 12 (Umetrics, Umea ˚, Sweden)
following log transformation, mean centering and UV-scaling
[50]. Model performance was reported as cumulative correlation
coefficients for the model (R
2Y[cum]) and predictive performance
based on seven-fold cross validation calculations (Q
2[cum]).
Results
Oxylipin profiling
A total of 87 oxylipins representing 3 metabolic pathways
(COX, LOX and CYP) were screened using LC-MS/MS analysis.
Of these, 32 oxylipins were detected above the method LOQ. An
additional 32 oxylipins were present above the method limit of
detection (LOD). A complete list of screened oxylipins as well as
the 32 oxylipins over the LOD, but under the LOQ, is provided in
Table S1. The oxylipin levels in the BALF (individuals from all 3
groups) ranged over 4 orders of magnitude from ,0.1 pM to
3 nM (Table S2). The average concentrations (pM) and the
coefficients of variance (CV) are given for the 3 different test
groups in Table 2 (i.e., Healthy Controls [HC], Asthmatic
Controls [AC] and Asthmatics Following Provocation [AFP]).
Asthmatics versus healthy controls at unprovoked
baseline levels
A total of 9 oxylipins were significantly elevated in the
asthmatics at unprovoked baseline levels relative to healthy
controls (,2-fold increase comparing the group averages in
Table 2; p#0.05). These oxylipins were 12- and 15-HETE,
epoxyketooctadecenoic acid (EKODE), 9,12,13-trihydroxyoctade-
cenoic acid (9,12,13-TriHOME), 15-hydroxyeicosatrienoic acid
(15-HETrE), 12(13)-epoxyoctadecadienoic acid (12(13)-EpODE),
12- and 15-hydroxyeicosapentaenoic acid (12- and 15-HEPE) and
17-hydroxydocosahexaenoic acid (17-HDoHE). With the excep-
tion of EKODE and 12(13)-EpODE, all other significantly
elevated oxylipins were most likely 15-LOX metabolites (Figure
S2). However, it is possible that P450 activity could account for
biosynthesis of some of the mono-hydroxy analogs [51].
Asthmatics following provocation
Following birch pollen provocation, 17 oxylipins were signifi-
cantly higher in the asthmatics relative to healthy controls (,1.5- to
3-fold increase based upon the group averages in Table 2; p#0.05).
The majorityofthesignificantly altered oxylipins(12out of17)were
15-LOX metabolites (Figure S2). With the exception of EKODE,
all of the oxylipins elevated in the asthmatic controls were further
elevated following provocation. In addition, significantly higher
concentrations were observed for 15-oxo-eicosatetraenoic acid (15-
KETE), 5,15-dihydroxyeicosatetraenoic acid (5,15-DiHETE), 6-
trans-LTB4, PGE2, 17-HDoHE, 13-HODE, 9,10,13-TriHOME,
9(10)-epoxyoctadecenoic acid (9(10)-EpOME), 9,10-dihydroxyocta-
decenoic acid (9,10-DiHOME) and 13-hydroxyoctadecatrienoic
acid (13-HOTE). When investigating intra-individual alterations in
Asthmatic Responses to Birch Pollen
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PUFA
a Oxylipin
b (pM)
Healthy controls
(HC)
Asthmatic
controls (AC)
Asthmatics following
provocation (AFP) Significance
c
HC/AC HC/AFP AC/AFP Trend
d
AV
e CV
f AV CV AV CV p p p p
AA
g 5-HETE 89 66 135 62 131 62 0.20 0.22 0.83 0.071
12-HETE 32 69 80 51 104 58 0.0081 0.012 0.30 0.022
15-HETE 337 73 734 66 991 63 0.046 0.022 0.066 0.091
15-KETE 110 64 252 76 294 62 0.080 0.026 0.28 0.091
5,6-DiHETE 2.6 89 3.1 65 3.7 74 0.68 0.42 0.48 0.030
5,15-DiHETE 5.4 98 11 65 12 57 0.085 0.048 0.79 0.028
11,12-DiHETrE 0.9 82 1.4 41 1.3 74 0.12 0.38 0.62 0.045
14,15-DiHETrE 2.9 50 3.6 20 3.3 35 0.24 0.57 0.56 0.070
11(12)-EpETrE 3.2 44 7.6 92 4.0 59 0.12 0.42 0.22 0.39
LTB4 53 71 72 59 81 53 0.35 0.17 0.44 0.020
6-trans-LTB4 22 56 32 58 39 45 0.18 0.030 0.051 0.030
TXB2 41 65 47 52 78 119 0.66 0.30 0.36 0.20
PGE2 5.1 64 6.1 33 9.8 56 0.44 0.046 0.16 0.040
PGD2 3.4 84 5.6 75 7.7 89 0.23 0.11 0.52 0.020
LA
h 9-HODE 201 66 224 55 190 63 0.73 0.85 0.63 0.20
9-KODE 129 73 197 77 138 68 0.27 0.84 0.21 0.37
13-HODE 785 74 1250 60 1530 51 0.17 0.039 0.15 0.022
EKODE 244 65 541 54 449 55 0.018 0.057 0.41 0.0060
9,10,13-TriHOME 68 43 122 61 104 25 0.087 0.016 0.52 0.022
9,12,13-TriHOME 279 46 537 54 516 27 0.043 0.0024 0.85 0.0060
9,10-DiHOME 221 53 440 69 463 57 0.090 0.039 0.82 0.0030
9(10)-EpOME 914 27 1370 49 1570 42 0.10 0.026 0.42 0.060
12,13-DiHOME 235 52 460 74 467 60 0.11 0.057 0.95 0.060
12(13)-EpOME 1000 30 1540 48 1770 38 0.086 0.16 0.39 0.060
DGLA
i 15-HETrE 38 63 81 59 116 71 0.032 0.031 0.18 0.091
a-LA
j 9-HOTE 8.0 63 9.4 44 6.8 41 0.56 0.54 0.16 0.41
13-HOTE 33 70 67 72 76 48 0.083 0.011 0.45 0.022
12(13)-EpODE 2.3 61 4.3 55 5.0 48 0.048 0.010 0.41 0.0030
EPA
k 5-HEPE 8.2 86 13 54 13 65 0.15 0.24 0.68 0.080
12-HEPE 6.2 52 16 58 17 38 0.021 0.00051 0.71 0.0030
15-HEPE 32 70 99 70 110 53 0.030 0.0064 0.27 0.091
DHA
l 17-HDoHE 162 65 452 76 517 60 0.051 0.014 0.59 0.0030
15-LOX
m v-6 (n=10)
n 1980 52 3490 46 4000 39 0.034 0.0064 0.29 0.022
v-3 (n=5) 242 60 644 70 727 53 0.040 0.0088 0.55 0.022
Total 15-LOX (n=15) 2230 52 4130 47 4720 41 0.025 0.0049 0.31 0.022
aPolyunsaturated fatty acid.
bOxylipin levels are reported as concentration (pM) and were normalized to the BAL volume recoveries. A complete list of all oxylipin acronyms is provided in Table S1.
cStatistical significance was calculated with either an unpaired or paired Student’s t-test. Values with p,0.05 are shown in italics with two significant figures.
dThe median concentration (pM) among the healthy controls (HC) regarding each oxylipin was used as a cut off limit for all three groups (i.e., Healthy Controls,
Asthmatic Controls and Asthmatics Following Provocation), with values provided in Table S8. All p-values regarding trend are one-sided.
eAverage,
fCoefficient of variance,
gArachidonic acid,
hLinoleic Acid,
iDihomo-c-linolenic acid,
ja-Linolenic acid,
kEicosapentaenoic acid,
lDocosahexaenoic acid.
m15-Lipoxygenase products.
nThe numbers in parentheses indicate the number of oxylipin species analyzed for each subgroup.
doi:10.1371/journal.pone.0033780.t002
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changes in oxylipin concentrations were detected (Table 2).
However, a significant trend in elevated 15-LOX-derived com-
pounds following provocation was observed (see below).
15-LOX metabolites and trend analysis
Based upon the observed shifts in oxylipin levels described
above, 15-LOX products were examined in further detail, both in
terms of the sum of all potential 15-LOX metabolites (n=15), as
well as based upon their parent polyunsaturated fatty acid
substrate divided as v-6 (n=10) and v-3 (n=5) fatty acids
(Table 2, Figure 1). The sum of 15-LOX metabolites as well as the
v-6 and v-3 grouped 15-LOX metabolites were all significantly
elevated in asthmatics at baseline levels (p=0.03, p=0.03 and
p=0.04, respectively). The significance further increased between
healthy controls and asthmatics following provocation (p=0.005,
p=0.006 and p=0.009, respectively). The corresponding group
comparison of allergic asthmatics before and after provocation did
not reach significance; however, a one-sided Cochran-Armitage
trend test confirmed that the increasing oxylipin levels between
healthy controls, asthmatic controls and asthmatics following
provocation evidenced a trend (Table 2). The trend was significant
both for the total sum of 15-LOX metabolites (p=0.02), and for
the v-6 (p=0.02) and v-3 (p=0.02) compounds compared
separately (Figure 1). Further examination of the individual
oxylipins revealed that the v-6 mediators 12-HETE, 5,15-
DiHETE, 13-HODE, 9,10,13- and 9,12,13-TriHOME as well
as the v-3 mediators 13-HOTE, 12-HEPE and 17-HDoHE
followed the same significant trend (Table 2, Figure S2). The trend
was particularly prominent for 12-HEPE (p=0.003) and 17-
HDoHE (p=0.003). The trend was not significant for the primary
15-LOX products 15-HETE (p=0.091) and 15-HEPE (p=0.091).
Examination of the trend significance for compounds outside of
the 15-LOX pathway evidenced additional shifts. The leukotrienes
(LTB4 and 6-trans-LTB4) and prostanoids (PGD2 and PGE2)a s
well as a number of CYP products (11,12-DiHETrE, 9,10-
DiHOME and 12[13]-EpODE) evidenced significant trends,
increasing in levels from healthy individuals to baseline asthmatics
Table 3. Cytokine and BAL cell levels in BALF from 1) Healthy controls 2) Asthmatic controls and 3) Asthmatics following
provocation.
a
Variable
Healthy controls
(HC)
Asthmatic
controls (AC)
Asthmatics
following
provocation (AFP) Significance
b
HC/AC HC/AFP AC/AFP Trend
c
AV
d CV
e AV CV AV CV p p p p
Age 25 17 30 25 30 25 0.15 0.17 0.35 N.D.
f
Mast cells 1.6 188 5.5 87 7.8 86 0.056 0.023 0.36 0.0050
Eosinophils 0.29 82 0.30 107 1.0 107 0.94 0.10 0.10 0.40
Neutrophils 1.3 49 0.60 73 1.2 73 0.017 0.66 0.093 N.D.
CD3+CD4+FOXP3 6.9 51 9.5 79 15 51 0.39 0.016 0.032 0.0070
CD3+CD45RO+ 15 57 15 126 16 120 1.0 0.91 0.93 0.20
CD3+CD4+CXCR3+CCR4+ 0.32 145 0.057 265 0.0 0.0 0.23 N.D. N.D. N.D.
CD3+CD4+CD161+ 10 63 6.4 119 8.1 70 0.32 0.50 0.71 0.43
CD3+CD8+CD161+ 10 101 2.9 87 7.6 154 0.11 0.67 0.24 0.087
CD3+CD11a+ 73 38 47 57 49 29 0.11 0.068 0.80 0.32
CD3-CXCR3+ 9.1 125 5.6 135 3.2 60 0.54 0.26 0.37 0.036
CD3-CD16+CD56+ 0.88 29 0.70 130 0.5 68 0.63 0.056 0.59 0.34
CD3-CD16+CD56+CXCR3+ 29 36 33 88 15 28 0.76 0.010 0.20 0.16
CD3-CD14+HLA-DR+ 73 38 47 57 49 29 0.11 0.068 0.86 0.036
IL-5 4.9 79 17 65 156 93 0.019 0.021 0.031 0.0060
IL-9 4.4 101 18 65 56 78 0.014 0.012 0.028 0.0030
IL-6 367 46 709 75 997 89 0.12 0.086 0.35 0.070
IL-10
g 5.4 144 5.5 67 9.4 76 0.97 0.29 0.043 0.071
aSelected variables displayed in Figure 4, cell populations are defined in Methods. Units for each of the variable groups are defined as: age (years), cell populations (% of
total population in BAL cells, except for mast cells, which are given as the number of cells per 10 visual fields in a Bu ¨rker chamber), immunological markers (proportion
of cells expressing a set of markers among another defined cell population as defined in Tables S4 and S5), and cytokines (fg/ml BALF) as reported in Thunberg et al.
[42].
bStatistical significance was calculated with either an unpaired or paired Student’s t-test. Values with p,0.05 are shown in italics with two significant figures.
cThe median levels among the healthy controls (HC) regarding each variable were used as a cut off limit for all three groups (i.e., Healthy Controls, Asthmatic Controls
and Asthmatics Following Provocation). All p-values regarding trend are one-sided.
dAverage.
eCoefficient of variance.
fN.D.=value not determined.
gThe IL-10 data consisted of a significant range in individual values, with one healthy individual possessing a value of 26.1 fg/ml, which did not pass a Qcrit test.
However, since this individual was included in the original Thunberg et al. [42] paper, it was not removed from this analysis. Exclusion of this individual from the trend
test gave p=0.042 and the resulting Student’s t-test values were: HC/AC p=0.08, HC/AFP p=0.04, and AC/AFP p=0.04.
doi:10.1371/journal.pone.0033780.t003
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was also examined for the cytokine and BAL cell data, with IL-5,
IL-9, mast cells and T regulatory cells (Treg) CD3+CD4+FOXP3
all evidencing trends that significantly increased from healthy
controls to provoked asthmatics (Table 3). IL-10 data consisted of
a significant range in individual values, with one healthy individual
possessing a value of 26.1 fg/ml, which did not pass a Qcrit test.
However, since this individual was included in the original
Thunberg et al. [42] paper, it was not removed from this analysis.
Exclusion of this individual from the trend test gave p=0.042.
Relative fatty acid class composition
To compare global shifts in lipid metabolites, oxylipin levels
were summed on the basis of their unsaturated fatty acid substrate
(e.g., AA). For example, all quantified oxylipins derived from AA
were summed on a concentration basis and presented as percent of
total quantified oxylipins. The average for the populations
evidenced that BALF was highly enriched in linoleic acid (LA)
metabolites, representing ,70–80% of the overall oxylipin content
as compared to ,10–20% of AA metabolites. Other fatty acid
classes (dihomo-c-linolenic acid [DGLA], a-linolenic acid [a-LA],
docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA])
only consisted of a few oxylipins relative to LA- and AA-derived
metabolites, which were the dominant compounds represented in
the oxylipin analytical method.
A comparison of the composition between the healthy and
asthmatic controls only showed significant differences in the EPA
metabolites (n=3), which contributed a significantly larger
proportion (p=0.04) to the overall asthmatic oxylipin profile
(1.3%) than the corresponding comparison of the pollen-exposed
asthmatics relative to healthy controls (0.9%; Figure 2A and
Figure 2B, Table S6). The relative composition of linoleates
(n=10) constituted a significantly smaller proportion (p=0.04) in
the profiles of pollen-exposed asthmatics (74.5%) compared to
healthy controls (81.1%), and a significant higher proportion
(p=0.02 and p=0.04, respectively) of the eicosapentaenoates
(n=3; 1.4% compared to 0.9%, respectively) and the docosahex-
aenoate (n=1; 5.0% compared to 3.1%, respectively; Figure 2A
and Figure 2C, Table S6). No significant alterations in fatty acid
class composition were detected comparing asthmatic control
profiles to the profiles following provocation. With the exception of
DHA (17-HDoHE; p=0.03), the Cochran-Armitage trend test did
not indicate any significant shifts comparing healthy controls,
Figure 1. Sum of 15-LOX metabolites. (A) Sum of 15-LOX metabolites from both v-3 and v-6 pathways. (B) Sum of 15-LOX metabolites from v-6
fatty acids (12-and 15-HETE, 15-KETE, 5,15-DiHETE, 13-HODE, 9,10,13- and 9,12,13-TriHOME, 9-HODE, 9-KODE and 15-HETrE), (C) Sum of 15-LOX
metabolites from v-3 fatty acids (9- and 13-HOTE, 12- and 15-HEPE and 17-HDoHE). Data are provided as concentration in BALF (pM). HC: Healthy
controls, AC: Asthmatic controls, AFP: Asthmatics following provocation. The p-values obtained using Student’s T-test (HC vs. AC and HC vs. AFP) and
one-sided Cochran-Armitage trend test (HC, AC and AFP) are indicated in the figure.
doi:10.1371/journal.pone.0033780.g001
Figure 2. Oxylipin composition based on polyunsaturated fatty
acid class. (A) Healthy controls (HC) (B) Asthmatic controls (AC) and
(C) Asthmatics following provocation (AFP). Oxylipins were grouped
into the following classes based upon their fatty acid substrate: linoleic
acid (LA), dihomo-c-linolenic acid (DGLA), arachidonic acid (AA), a-
linolenic acid (a-LA), eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA). Healthy controls and asthmatics following provocation
evidenced significant differences for LA (p=0.04), EPA (p=0.02) and
DHA (p=0.04). The proportion of EPA metabolites was also significantly
higher in asthmatic controls compared to healthy controls (p=0.04).
doi:10.1371/journal.pone.0033780.g002
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shown).
Oxylipin levels of LA and AA origin were also summed on the
basis of functional group or molecular class (e.g., alcohols, ketones,
epoxides and diols). The main difference in distribution was
observed in the epoxides, LA (,60%) compared to AA (,1%;
Figure S3). No significant differences were detected between
healthy controls and the asthmatic groups.
Integrated multivariate modeling
Multivariate statistical modeling integrating oxylipin data with
previously published clinical information (FACS characterizations
of BAL cells, cytokine and differential inflammatory cell data [42])
was performed in order to investigate the utility and biological
relevance of oxylipin levels in the light of established inflammatory
markers. OPLS analysis with respect to separation according to
diagnosis was performed for A) Healthy Controls and Asthmatic
Controls (Figure 3A) and B) Healthy Controls and Asthmatics
Following Provocation (Figure 3B). The resulting models were
termed ‘‘Baseline Asthmatics’’ and ‘‘Provoked Asthmatics’’, respec-
tively. OPLS is a supervised multivariate method that allows
extraction of the variance of interest (here the difference between
asthmatics and healthy) from the unrelated (orthogonal) noise in the
data set. This separation of the predictive variance from the
orthogonal variance greatly improves the interpretability of the
resulting model, because the contribution of the specific original
data variables (e.g., oxylipins)can easily be derived from the loadings
of the single predictive vector [50]. Both OPLS models were
constructed from one predictive and one orthogonal component,
with both resulting in a good separation between healthy controls
and asthmatics (Baseline Asthmatics: R
2Y[cum]=0.87, Provoked
Asthmatics: R
2Y[cum]=0.95). Seven-fold cross validation revealed
that the models were robust (Baseline Asthmatics: Q
2[cum]=0.51,
cross-validated analysis of variance (CV-ANOVA)=0.15; Provoked
Asthmatics: Q
2[cum]=0.73, CV-ANOVA=0.01 ), corresponding
to 51% predictive power at unprovoked baseline levels, and 73%
predictive power following allergen provocation. The subject
located outside of Hotelling’s T
2 in the Baseline Asthmatics model
(Subject 1, Figure 3A) was an outlier only in terms of the orthogonal
vector, and further examination of the Distance to Model X
(DModX) confirmed that this individual was within the 95%
confidence interval. As such, the potential outlier was not removed
from further analyses. The loading column plots (Figure 3; A)
n=21; B) n=32) show that predominantly the cytokine and
oxylipin variables drive the separation between groups.
Comparison between the two models (Baseline Asthmatics and
Provoked Asthmatics) was performed using a Shared and Unique
Structures (SUS) plot, in which the loadings of the predictive
vectors for the two models are plotted against each other to reveal
differences and similarities in the variable contribution between
Figure 3. OPLS score and loading column plots with respect to separation according to diagnosis. Loading column plots visualize
variables correlating with healthy (2) or asthmatics (+), error bars indicate 95% confidence interval. The number of variables correlating with the
asthmatic population with 95% confidence increases following provocation from n=21 to n=32. (A) Healthy controls (green) and asthmatic controls
(yellow) (R
2Y[cum]=0.87, Q
2[cum]=0.51). (B) Healthy controls (green) and asthmatics following provocation (red) (R
2Y[cum]=0.95, Q
2[cum]=0.73).
doi:10.1371/journal.pone.0033780.g003
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scaled as a correlation coefficient (p[corr]) between the actual
datum points (X-matrix) and the corresponding scores vector (t),
making the plot interpretation more intuitive. A high p(corr)
indicates a high prominence of the variable in driving the
separation between groups in the particular model. For example,
the relatively higher p(corr) for IL-10 in the Provoked Asthmatics
model (0.5), compared to the Baseline Asthmatics model (0.1),
indicates that IL-10 is more important for driving the separation
between healthy and asthmatics following allergen provocation
than at baseline levels. The SUS plot can be interpreted based
upon variable location in the plot, with shared variables located on
the diagonal (either positive or negative) and unique effects for
Baseline Asthmatics and Provoked Asthmatics found closer to the
X- or Y-axis, respectively.
The SUS plot demonstrated a strong positive correlation of the
variable contribution between the two models (R
2=0.7, Figure 4).
The primary shared structures were the 15-LOX-derived v-6 and
v-3 metabolites, the cytokines IL-5 and IL-9 as well as the mast
cells, which all showed robust positive correlation with the
asthmatic individuals in both models (Figure 4). However, the
15-LOX v-3 oxylipins had a slightly stronger contribution to the
Provoked Asthmatics model. In particular, the p(corr) values for
both 15-HEPE and 13-HOTE were 0.4 and 0.7 for the Baseline
Asthmatics and Provoked Asthmatics models, respectively
(Figure 4, Table S7). In contrast, the 15-LOX v-6-derived
oxylipins evidenced little variation between the two models, with
15-HETE, 15-KETE, 15-HETrE and 13-HODE possessing
similar p(corr) values (p[corr]=0.4 and 0.6 for the Baseline
Asthmatics and Provoked Asthmatics, respectively; Figure 4, Table
S7). The COX-derived v-6 oxylipins PGE2 and PGD2 co-
localized in the SUS plot, with little contribution to the separation
between groups. IL-5 and IL-9 had the strongest contributions to
driving the overall models with p(corr) values ranging from 0.7–0.9
for both Baseline and Provoked Asthmatics. Mast cell abundance
had a weaker, but identical, contribution to both Baseline and
Provoked asthmatics (p[corr]=0.6).
The primary unique structures were the CYP-derived linoleic
acid products, which were more prominent variables in the
Provoked Asthmatics model. The strongest contributions were
from the epoxides 9(10)-EpOME and 12(13)-EpOME, which
shifted from no contribution at Baseline levels (p[corr]=0.0–0.1)
to 0.5 and 0.6 respectively for the Provoked Asthmatics model
(Table S7). The corresponding diols, 9,10-DiHOME and 12,13-
DiHOME, evidenced a similar shift, but with slightly stronger
contributions at Baseline levels (p[corr] values for both species
shifted from 0.2 to 0.6). The 5-LOX-derived v-6 oxylipins LTB4
and 6-trans-LTB4 were also unique for the Provoked Asthmatics
model, but with slightly weaker contributions (p[corr]=0.4–0.5).
The only oxylipin variables to contribute stronger to the Baseline
Asthmatics models were the v-6 AA diols 11,12-DiHETrE and
14,15-DiHETrE, which exhibited p(corr) values of 0.2 for
Provoked Asthmatics relative to 0.5 and 0.4 for Baseline
Asthmatics, respectively (Figure 4, Table S7). In terms of the
cytokines and inflammatory cells, the unique variables for the
Provoked Asthmatics were IL-10 and eosinophil abundance,
which both possessed p(corr) values of 0.5 relative to 0.1 for
Baseline Asthmatics (Figure 4, Table S7). In addition,
CD3+CD4+FOXP3+ Treg cells contributed stronger to the
Provoked Asthmatics model with a p(corr) of 0.6 relative to 0.2
for Baseline Asthmatics (Figure 4, Table S7). CD3-
CD16+CD56+CXCR3+ cells evidenced an inverse contribution
to the Provoked Asthmatics model (p[corr]=20.7).
Discussion
One of the primary observations in this study was that asthmatic
controls demonstrated a distinct lipid mediator profile relative to
healthy controls. These individuals are mild intermittent asthmat-
ics that are essentially ‘‘healthy’’ at baseline when no allergen
Figure 4. Shared and Unique Structures (SUS) plot. SUS plot correlating the OPLS models of healthy controls versus asthmatic controls
(Baseline Asthmatics, Figure 3A, X-axis) and healthy controls versus asthmatics following provocation (Provoked Asthmatics, Figure 3B, Y-axis). A
complete list of p(corr) values for both models is provided in Table S7. Abbreviations are as follows: 15-lipoxygenease (15-LOX), cyclooxygenase
(COX), 5-lipoxygenase (5-LOX), cytochrome P450 (CYP), v-6 fatty acid (v-6), v-3 fatty acid (v-3), healthy controls (HC), asthmatic controls (AC) and
asthmatics following provocation (AFP). Colors are as follows: 15-LOX-derived v-3 oxylipins (blue), 15-LOX-derived v-6 oxylipins (red), COX-derived v-
6 oxylipins (green), 5-LOX-derived v-6 oxylipins (orange), CYP-derived v-6 oxylipins (gold). Variables with p(corr)$|0.4| are labeled, while those #|0.4|
are shown as symbols.
doi:10.1371/journal.pone.0033780.g004
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pattern of elevation in 15-LOX metabolites observed following
allergen provocation was present at baseline levels. Of the altered
15-LOX-derived compounds, AA-derived 15-HETE is the most
well known indicator of pro-inflammatory responses in asthma
[31,32]. It is likely that the significantly elevated levels of 15-
HETE in baseline asthmatics signify pro-inflammatory processes
active in stabile, unprovoked mild asthmatics, which are further
amplified following allergen provocation.
The ratio of 15-HETE levels in BALF for baseline asthmatics
vs. healthy individuals was 2:1, which agreed with previous
studies [32,47]. A comparison of all 15-LOX products from AA-
derived oxylipins gave a ratio of $2 between asthmatics and
healthy individuals, whereas for LA-derived oxylipins the ratios
were #2 (in agreement with earlier results [47]). The ratios of 15-
LOX products from v-3 fatty acids were all $2b e t w e e n
asthmatics and healthy individuals, which differs from our earlier
studies of mild intermittent asthmatics [47]. This observation may
reflect higher variability in v-3-derived oxylipins, which could in
part be a function of their lower physiological levels. The
biological significance of the differing ratios is unclear, but
becomes more interesting when examined in terms of BALF
composition, of which LA-derived oxylipins are the dominant
species (Figure 2). For example, in the global oxylipin profile
based on relative fatty acid mediator composition (%), the ratios
of LA:AA metabolites were similar for healthy and asthmatic
controls (6.6 and 5.9, respectively compared to 5.2 for allergen
provoked asthmatics). However, we have previously observed
significant differences in BALF oxylipin LA:AA ratios of healthy
(LA:AA=6.3) and baseline asthmatics (LA:AA=3.4) [47]. These
observations suggest that biological processes related to AA-
derived oxylipins play a more prominent role in asthmatics
relative to LA-derived mediators. These differences potentially
reflect shifts in 15-LOX activity between the different groups and
given the biological significant of these oxylipin mediators,
warrant further investigation.
Some of the individual oxylipins quantified in this study have
been previously examined in pulmonary disease (see Lundstro ¨m et
al. for a comprehensive review [24]), but there is only one known
previous study performing oxylipin metabolic profiling in BALF
from asthmatics [47] and no known studies from other
inflammatory conditions (e.g., COPD, hypersensitivity pneumonitis
or sarcoidosis). To place our findings within the context of the
known literature, we have examined a few of the well-described
compounds in terms of their contribution to the multivariate
modeling. Prostanoids are potent mediators of inflammation in
asthma that evidenced Shared (equal) contributions to the Baseline
and Provoked Asthmatics models in the SUS plot. The biological
role of PGD2 and PGE2 in allergic inflammation is multifaceted,
with PGD2 causing bronchoconstriction, elevating Th2 cytokines
[53] and eosinophil infiltration into the lung; roles that are
consistent with the location of PGD2 in the SUS plot. PGE2 on the
other hand prevents allergen-induced bronchoconstriction [21],
decreases airway eosinophilia [54] and activates mast cells [55].
The proximity of PGE2 in the SUS plot to eosinophils and IL-10
potentially suggests ongoing suppression of eosinophilia, which
would be expected at 24 h post-allergen exposure. The multivar-
iate modeling shows that the pro-inflammatory cytokines in
combination with the anti-inflammatory oxylipins contribute
strongly and similarly to the models in both Baseline and
Provoked Asthmatics at 24 h, suggesting that these mediators do
not play a significant role in allergen-specific processes. While the
trend is significant, the prostanoids have an overall weaker
contribution to the model. Accordingly, it is possible that these
variables are a reflection of the overall inflammatory state in these
asthmatics, which is further amplified following allergen-provoca-
tion; however, no new pathways are affected during this process.
This interpretation is supported by the significant trend of
increasing levels for the majority of the quantified 15-LOX-
derived oxylipins.
The multivariate model was also interrogated for allergen-
specific processes, with the Provoked Asthmatics model illustrating
a similar mix of pro- and anti-inflammatory markers. In this phase,
eosinophils significantly increased, most likely accounting for the
corresponding increase in leukotrienes (e.g.,6 - trans-LTB4). How-
ever, eosinophils are suppressed by IL-10 [56], which also
increased following allergen provocation. The eosinophils and
the LA-derived CYP-produced EpOMEs and DiHOMEs shifted
from essentially no contribution (p[corr]#0.1) to the principle
unique driving variables in the Provoked Asthmatics model
(p[corr]$0.6; Figure 4). This shift in the SUS plot evidences an
effect on the atopic asthmatic lung from birch pollen that was not
observed in unprovoked asthmatics. Extreme levels of EpOMEs
and DiHOMEs are associated with acute respiratory distress
syndrome (ARDS), in which high levels are detected (e.g.,
38.5621.9 nM for 9[10]-EpOME) [57,58]. In the current study,
levels were much lower, but still evidenced a significant increase in
asthmatics following provocation (1.660.4 nM relative to
0.960.3 nM for healthy controls). In contrast, the increase in
CD3+CD4+FOXP3+ Treg cells following allergen provocation
may be indicative of an attempt to launch an anti-inflammatory
response in these mildly asthmatic subjects (Figure 4). However,
Hartl et al. [59] showed that asthmatic children were associated
with a decreased number of Treg cells, which were also shown to
possess an impaired functionality, rendering the subject with an
inability to regulate the allergen-induced inflammation. Likewise,
in vitro stimulation studies performed by Thunberg et al. [42] on
primary peripheral blood mononuclear cells (PBMCs) from the
same subjects in this study showed an inability to suppress Th2
responses, indicating that the infiltrating FOXP3+ cells are not
able to control the allergen-induced Th2 response [42]. The
enhanced levels of pro-inflammatory oxylipins such as the 15-
LOX-derived v-6 oxylipins and leukotrienes provide further
support of these conclusions.
This study focused on allergen-provoked asthmatics at the 24 h
time point. Allergen inhalation by allergic asthmatics has two
distinct temporal components: 1) The first event is the allergen-
induced early asthmatic response (or the immediate IgE-mediated
reaction), which involves an acute bronchoconstrictor response
that develops within 15 min and usually resolves within 2 h and 2)
the second period of bronchoconstriction or the late asthmatic
response beginning 3–4 h after inhalation, often peaking at 6–9 h,
and lasting up to 24 h [8,22]. The late-phase reaction often
consists of Th2 cells, which affects the cytokine environment and
eosinophil levels [60,61]. Accordingly, the snapshot of mediators
acquired in this study provides an image of the allergic response as
it shifts towards a resolution phase. While no oxylipins known to
be directly involved in this phase (e.g., lipoxins, resolvins or
protectins [17]) were observed, a number of v-3 products
including the 15-LOX-derived 17-HDoHE were increased at
24 h. 17-HDoHE is derived from the 17-HPDoHE peroxide
precursor, which can alternatively be converted to the 17-D series
of resolvins (17-RvDs) [17]. These observations in combination
with the IL-10 and CD3+CD4+FOXP3+ data are suggestive of a
shift towards an anti-inflammatory milieu at this stage.
Taken together these results indicate that 1) even mild allergic
asthmatics have altered oxylipin profiles relative to healthy
controls, 2) these differences are further augmented by allergen-
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background asthma-based pathology at baseline and 3) by 24 h
post-allergen exposure, mild allergic asthmatics exhibit a mixed
pro- and anti-inflammatory phenotype that is most likely
indicative of an ongoing resolution process. It is also possible that
oxylipins are more long-lived and subsequently the late asthmatic
phase is longer than expected, which was not observed with other
inflammatory markers. This theory would require confirmation
via time course-based studies designed to quantify oxylipin half-life
throughout the inflammatory process.
Conclusion
The oxylipin profile of mild allergic asthmatics is distinct from
that of the healthy lung at baseline and these differences are
amplified following birch allergen provocation. The predominant
shifts were in the 15-LOX pathway, further stressing the role of
this pathway in asthma pathology. The simultaneous elevation of
both pro- and anti-inflammatory oxylipins was highlighted by
multivariate analyses, in which cytokine levels in combination with
inflammatory cell data also correlated with asthmatics both at
baseline levels and following provocation. The observation that
allergen exposure amplified an existing underlying difference
between healthy subjects and baseline asthmatics indicates the
presence of a basal level of inflammation. These asthmatics were
non-symptomatic, stable subjects with mild intermittent asthma,
yet still evidenced a distinct quantifiable inflammatory signature
associated with disease pathology that was not discernable by
traditional inflammatory mediators (with the exception of a slight
elevation of IL-5 in BALF [42]). Accordingly, these results provide
further support for the use of oxylipin profiling as a more nuanced
and sensitive means of detecting underlying low levels of
inflammation in asthmatics and potentially other respiratory
disorders. In addition, the significant shifts in the oxylipin
signature between the baseline asthmatics and healthy controls
suggests that even non-symptomatic individuals possess unique
disease-specific phenotypes/metabotypes that have clinical rami-
fications as well as provide insight into the etiology and pathology
of disease.
Supporting Information
Figure S1 Sample chromatograms from the oxylipin
metabolic profiling method. A) Full chromatogram from
asthmatic individual7 inTable 1 followingprovocationshowingthe
range of oxylipins detected. B) Extracted ion chromatograms for
selected compounds (PGD2 and PGE2;6 - trans-LTB4, LTB4,a n d
purported isomers; 5,6-DiHETE and purported isomers). Peaks
shaded black indicate integrated peaks, while non-shaded peaks
possess the same mass transition and represent potential isomers;
however, are not reported due to a lack of analytical standards.
(TIF)
Figure S2 Oxylipins derived from the 15-LOX pathway.
A) Oxylipins derived from v-6 fatty acids (AA, DGLA, and LA). B)
Oxylipins derived from v-3 fatty acids (a-LA, EPA, and DHA).
HC: healthy controls, AC: asthmatic controls, AFP: asthmatics
following provocation. Numbers shown in each graph are the p-
values obtained using a Student’s T-test (HC vs AC and HC vs
AFP, respectively). The p-values for the one-sided Cochran-
Armitage trend test (HC, AC and AFP) are indicated below each
graph.
(TIF)
Figure S3 Oxylipin class profiles for linoleic acid- (LA)
and arachidonic acid- (AA) derived compounds. No
significant differences were detected between healthy controls
and asthmatics. Alcohols: LA (13-HODE and 9-HODE), AA (5-
HETE, 12-HETE and 15-HETE). Ketones: LA (9-KODE), AA
(15-KETE). Epoxides: LA (9(10)-EpOME and 12(13)-EpOME),
AA (11(12)-EpETrE). Diols: LA (9,10-DiHOME and 12,13-
DiHOME) and AA (LTB4,6 - trans-LTB4, 5,15-DiHETE, 11,12-
DiHETrE, 14,15-DiHETrE and 5,6-DiHETE). An oxylipin
nomenclature list is provided in Table S1.
(TIF)
Table S1 Standard list, nomenclature and information
on detected and quantified oxylipins in the study.
Standards include analytical-, deuterated internal- and technical
standards. Yellow markings indicate if oxylipins were assigned
over the limit of detection (LOD) or limit of quantification (LOQ).
(XLSX)
Table S2 Absolute concentrations of quantified oxyli-
pins not adjusted to bronchoalveolar lavage (BAL)
recovery volumes. Concentrations are given in pM.
(XLSX)
Table S3 Bronchoalveolar lavage (BAL) recoveries of
instilled and recovered volume in participating subjects.
Volumes are given in mL.
(XLSX)
Table S4 FACS panels. A list of the fluorophor conjugated
antibodies to the listed surface markers (Except FOXP3, which is
intracellular).
(XLSX)
Table S5 FACS cell populations. The quantified cell
populations among lymphocytes or total BAL cells are defined
by the FACS gating strategy as percentage within defined gates, as
shown within parentheses.
(XLSX)
Table S6 Relative percent composition of quantified
oxylipins on an individual and fatty acid class-specific
basis.
(XLSX)
Table S7 List of p(corr) values from the OPLS models.
(XLSX)
Table S8 Oxylipin concentrations in BALF from 1)
Healthy controls 2) Asthmatic controls and 3) Asthmat-
ics following provocation provided in units of median
with min/max values. Concentrations are given in pM.
(XLSX)
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